A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress

Clinical and Translational Allergy

Jean Bousquet²  Ruth Murray⁶  Pascal Demoly^1,12  Gerd Rasp⁹  Glenis Scadding⁵  Nikos Papadopoulos⁷  David Price^1,11  G. Walter Canonica⁸  Claus Bachert³  Joaquim Mullol⁴  Wytske Fokkens¹  Antonella Muraro^1,10  Peter W. Hellings¹ 

[1] Department of Otorhinolaryngology, Academic Medical Center (AMC), Amsterdam, The Netherlands;UVSQ UMR-S1168, Universite Versailles St-Quentin-en-Yvelines, Versailles, France;Upper Airways Research Laboratory (URL), University Hospital Ghent, Ghent, Belgium;Hospital Clinic, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain;RNTNE Hospital, London, UK;MedScript Ltd, Dundalk, Co. Louth, Ireland;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece;Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS S Martino, IST, University of Genoa, Genoa, Italy;Department of Otorhinolaryngology, Paracelsus Medical University, Salzburg, Austria;Department of Women and Child Health, Food Allergy Referral Centre, Padua University Hospital, Veneto Region, Padua, Italy;Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK;Division of Allergy, Department of Pulmonology, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France

关键词: VAS;    Visual analogue scale;    Survey;    Digital;    Control;    Allergic rhinitis;   

Others  :  1231127
DOI  :  10.1186/s13601-015-0080-9

 received in 2015-07-31, accepted in 2015-09-23,  发布年份 2015

【 摘 要 】

Background

The concept of control is gaining importance in the field of allergic rhinitis (AR), with a visual analogue scale (VAS) score being a validated, easy and attractive tool to evaluate AR symptom control. The doctors’ perception of a VAS score as a good tool for evaluating AR symptom control is unknown, as is the level of AR control perceived by physicians who treat patients.

Methods

307 voluntarily selected physicians attending the annual (2013) European Academy of Allergy and Clinical Immunology (EAACI) meeting completed a digital survey. Delegates were asked to (1) estimate how many AR patients/week they saw during the season, (2) estimate the proportion of patients they considered to have well-, partly- and un-controlled AR, (3) communicate how they gauged this control and (4) assess how useful they would find a VAS as a method of gauging control. 257 questionnaires were filled out completely and analysed.

Results

EAACI delegates reported seeing 46.8 [standard deviation (SD) 68.5] AR patients/week during the season. They estimated that 38.7 % (SD 24.0), 34.2 % (SD 20.2) and 20.0 % (SD 16.34) of their AR patients had well-controlled (no AR symptoms), partly-controlled (some AR symptoms), or un-controlled-(moderate/severe AR symptoms) disease despite taking medication [remainder unknown (7.1 %)]. However, AR control was assessed in many ways, including symptom severity (74 %), frequency of day- and night-time symptoms (67 %), activity impairment (57 %), respiratory function monitoring (nasal and/or lung function; 40 %) and incidence of AR exacerbations (50 %). 91 % of delegates felt a simple VAS would be a useful tool to gauge AR symptom control.

Conclusions

A substantial portion of patients with AR are perceived as having uncontrolled or partly controlled disease even when treated. A simple VAS score is considered a useful tool to monitor AR control.

【 授权许可】

   
2015 Hellings et al.

【 图 表 】

Fig.1.

【 参考文献 】

• [1]Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A: Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014, 2:CD009122.
• [2]Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D, et al.: Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013, 68:1-7.
• [3]Mullol J, Bartra J, Del CA, Izquierdo I, Munoz-Cano R, Valero A: Specialist-based treatment reduces the severity of allergic rhinitis. Clin Exp Allergy 2013, 43:723-729.
• [4]Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Sa-Sousa A, Azevedo LF, Ferreira J, et al.: Control of Allergic Rhinitis and Asthma Test (CARAT) can be used to assess individual patients over time. Clin Transl Allergy. 2012, 2:16. BioMed Central Full Text
• [5]Linhares DV, da Fonseca JA, Borrego LM, Matos A, Pereira AM, Sa-Sousa A, et al.: Validation of control of allergic rhinitis and asthma test for children (CARATKids)—a prospective multicenter study. Pediatr Allergy Immunol 2014, 25:173-179.
• [6]Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P: Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy 2013, 43:881-888.
• [7]Bousquet PJ, Bachert C, Canonica GW, Casale TB, Mullol J, Klossek JM, et al.: Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010, 126:666-668.
• [8]Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Braun JJ, et al.: Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013, 3:7. BioMed Central Full Text
• [9]Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al.: Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J 2014, 44:304-323.
• [10]Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP, et al.: Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007, 62:367-372.
• [11]Bousquet PJ, Combescure C, Klossek JM, Daures JP, Bousquet J: Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol. 2009, 123:1349-1354.
• [12]Meltzer EO: Allergic rhinitis: the impact of discordant perspectives of patient and physician on treatment decisions. Clin Ther 2007, 29:1428-1440.
• [13]Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC: A survey of the burden of allergic rhinitis in Europe. Allergy 2007, 62(Suppl 85):17-25.
• [14]Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S: The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol. 2012, 8:7. BioMed Central Full Text
• [15]Fromer LM, Ortiz G, Ryan SF, Stoloff SW: Insights on allergic rhinitis from the patient perspective. J Fam Pract 2012, 61:S16-S22.
• [16]Bousquet J, Bachert C, Canonica GW, Mullol J, Van CP, Bindslev-Jensen C, et al.: Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy 2009, 64:1516-1523.
• [17]Bousquet J, Bachert C, Canonica GW, Mullol J, Van CP, Bindslev-Jensen C, et al.: Efficacy of desloratadine in persistent allergic rhinitis—a GA(2)LEN study. Int Arch Allergy Immunol 2010, 153:395-402.
• [18]Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, et al.: Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015, 36:40-47.
• [19]Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J: Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol 2013, 160:393-400.